ADVANCING INCLUSIVE RESEARCH®

Always Design with Patient Equity in Mind

Clinical studies offer people with serious and life-threatening diseases a chance to receive investigational medicines that can potentially improve outcomes. At Genentech, we are deeply committed to addressing barriers to clinical study participation and advancing inclusive research.

Learn more about how Genentech seeks to create more equitable health outcomes through inclusive research.


WHY INCLUSIVE RESEARCH?

More must be done to ensure clinical trial participants are representative of the entire patient population.

  • <10% Today, fewer than 10% of U.S. patients participate in clinical trials and of those only 5-15% are non-European.1
  • ~50% Yet, approximately half of the U.S. population is projected to be non-white by 2044.2
  • >94% More than 94% of genomic material available to scientists is of European ancestry.3

STRATEGIC FOCUS AREAS

REIMAGINING CLINICAL STUDIES

EMPOWERING PATIENTS & PROVIDERS

COLLABORATING WITH EXTERNAL PARTNERS

Click each dropdown to see our impact in action:


ADVANCING INCLUSIVE RESEARCH® SITE ALLIANCE

The U.S. Advancing Inclusive Research Site Alliance is a coalition of clinical research sites in oncology and ophthalmology that partner with Genentech to advance the representation of diverse patient populations in our clinical trials, test recruitment and retention approaches, and establish best practices that can be leveraged across the industry to help achieve health equity. Meet our site alliance champions.

I believe inclusive research is research—full stop. One day we won’t need the qualifier inclusive because all clinical studies will represent the diversity of the patients we serve.

Quita Highsmith, MBA, Vice President & Chief Diversity Officer, Genentech

At Roche and Genentech, we believe that improving health outcomes for all patients is core to our mission, and we are committed to being industry leaders in delivering improved health outcomes for all...


REFERENCES
1 Nabhan C, Choueiri TK, Mato AR. Rethinking Clinical Trials Reform During the COVID-19 Pandemic. JAMA Oncol. 2020;6(9):1327-1329. doi:10.1001/jamaoncol.2020.3142; for non-Caucasian participation (Hispanic and Latino): Coakley M, Fadiran EO, Parrish LJ, Griffith RA, Weiss E, Carter C. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials . J Womens Health (Larchmt). Jul 2012;21(7):713-6. doi:10.1089/jwh.2012.3733
2 Colby SL, Ortman JM. Rethinking Projections of the Size and Composition of the U.S. Population: 2014 to 2060.
3 Genomic Data Source: Rethinking Total GWAS Participants Diversity. GWAS Diversity Monitor.